http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
CNBX Pharmaceuticals Granted Patent in Hong Kong
-
Cannabics Pharmaceuticals Changes Name to CNBX Pharmaceuticals
-
CNBX Selects API Supplier Purisys to Support Planned IND Fillings and Phase I/II (a) Clinical Trials
-
Meet CNBX at Radiation Therapy Conference (RTC) 2021 in Chicago
-
Radiation Oncology Expert Joins Cannabics Pharmaceuticals' Board of Advisors
-
EDISON Publishes Healthcare QuickView on Cannabics Pharmaceuticals: CNBX
-
CNBX Director, Dr. Inbar Maymon-Pomeranchik, to Participate at MJBizCon in Las Vegas
-
CEO of Cannabics Pharmaceuticals, Eyal Barad, to present at Edison Open Forum: Cannabinoids 2021
-
Cannabics Pharmaceuticals Files 2 Provisional Patents On Compositions and Methods for Treating Cancer
-
CEO Eyal Barad and Dr. David Sans from Cannabics Pharmaceuticals in NYC, to Participate at Benzinga's Cannabis Capital Conference
-
Cannabics Announces New Corporate Logo, New Website and New Company Presentation
-
Gabriel Yariv, Executive Director of Cannabics Pharmaceuticals and Dr. David Sans will participate at the ICDP Summit in Boston
-
Cannabics Pharmaceuticals hires Healthcare Investment Banker Dr. David Sans in New York to expand CNBX in Mental Health Diseases
-
Neuropsychiatry Expert Dr. Ilya Reznik (MD) Joins Cannabics as Head of Psychedelic Inspired Medicine
-
Hemato-Oncology Expert, Dr. Sigal Tavor (MD) Joins Cannabics Pharmaceuticals' Board of Advisors
-
World-Renowned Melanoma Expert Joins Cannabics Pharmaceuticals' Board of Advisors
-
Cannabics Pharmaceuticals Appoints a Second Independent Board Member
-
Cannabics Pharmaceuticals Announces Appointment of New Independent Board Member
-
Cannabics Pharmaceuticals' Drug Candidate Exhibits 30% Tumor Volume Reduction in Mice
-
Cannabics Pharmaceuticals to launch Drug Development Programs for Prostate Cancer and Neurodegenerative & Mental Health Diseases
-
Cannabics Pharmaceuticals Launches a Breast Cancer Treatment Research Program
-
The European Patent Office Grants Cannabics Pharmaceuticals Patent for Company's Personalized Medicine Drug Discovery Technology
-
Cannabics Pharmaceuticals Files a PCT Patent Application for Proprietary Cancer Treatment Formulations
-
Cannabics Pharmaceuticals Receives Patent "Notice of Allowance" From The Mexican Patent and Trademark Office (IMPI)
-
Cannabics Pharmaceuticals Launches a New Research Program to develop a Melanoma Treatment Drug Candidate for FDA Approval Track
-
Cannabics Pharmaceuticals Launches Psilocybin and Psilocin Research Program
-
Cannabics Pharmaceuticals to Initiate in-vivo Dose Response Study on Proprietary Colorectal Cancer Drug Candidate RCC-33
-
Cannabics Pharmaceuticals' Drug Candidate RCC-33 Prolongs Survival Rate in Mice Inoculated with Human Colorectal Cancer Cells
-
Cannabics Pharmaceuticals' in-vivo Tumor Inhibitory Effect Study Concludes with a Statistical Significance of p ≤ 0.016
-
Cannabics Pharmaceuticals' in-vivo Study concludes with a 33% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer
-
Cannabics Pharmaceutical's Interim in-vivo Study Results Show a 27% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer
-
Cannabics Pharmaceuticals Initiates In-Vivo Animal Studies for FDA Pre-IND Meeting Package
-
Cannabics Pharmaceuticals Founds Digestix Bioscience Inc., a Subsidiary for Treatment of Precancerous and Early Stage Neoplastic Local Tumors
-
Cannabics Concludes a Pre-Clinical Study on Human Biopsies in Preparation for FDA pre-IND Meeting Request on Colorectal Cancer Drug Candidate RCC-33
-
Cannabics Pharmaceuticals receives "Intention to Grant a European Patent" notice for its System and Method for High Throughput Screening of Cancer Cells patent application
-
Cannabics Pharmaceuticals Prepares to Submit the FDA with a pre-IND Meeting Request for its Proprietary Colon Cancer Drug Candidate, CANNABICS™ RCC-33
-
Cannabics Pharmaceuticals to Establish a Division for its Antitumor Drug Candidate RCC-33
-
Cannabics Pharmaceuticals Appoints Dr. Dana Ben-Ami Shor (MD), Gastroenterologist, to its Scientific Board of Advisors
-
Cannabics Pharmaceuticals Initiates Penetration for Its Cannabinoid Diagnostic Platform Into European Markets
-
Cannabics Pharmaceuticals Appoints Dr. Erez Scapa, MD to its Scientific Board of Advisors
-
Cannabics Pharmaceuticals and Cannomed Collaborate to Develop Cannabis Strains Targeting Cancers
-
Cannabics Pharmaceuticals to Capitalize on Israel's Final Approval for the Export of Medical Cannabis
-
Cannabics Pharmaceuticals Files Provisional Patent on Composition and Method for Treating Colon Cancer With Cannabinoids
-
Cannabics Pharmaceuticals Appoints Prof. Zamir Halpern to Its Scientific Board of Advisors
-
Cannabics Pharmaceuticals Develops Novel Cannabis Formulation for the Treatment of Colon Cancer
-
Cannabics Pharmaceuticals Study Shows Complex Combinatorial Anti-tumor Activity of Cannabinoids
-
Cannabics Pharmaceuticals Offers Its High Throughput Screening (HTS) Platform to the Israeli Health Authorities for SARS-CoV-2 Research
-
Cannabics Pharmaceuticals Shows Specific Cultivars Identified to Have Positive Anti-Tumor Effects on Gastric Adenocarcinoma
-
Cannabics Pharmaceuticals Reveals Different Extraction Methods Result in Differential Necrotic Effects of Cannabis on Gastrointestinal Cancer Cells
-
Cannabics Pharmaceuticals Partners With NewCanna to Commence Research Based on Colombian Indigenous Cannabis Landraces
